Frontiers in Immunology · 2023 · 17 citations · 45 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyOncogenesCancer ImmunotherapyCheckpoint Inhibitor TherapyMicrorna BiologyMicrorna-mediated RegulationTargeted Cancer TherapyTargeted TherapyCell Death In CancerCell Viability AssaysCytotoxicity AssaysMicrorna In CancerMicrorna Regulation In CancerMicrorna TherapeuticsMicrorna-mediated OncogenesisSiglec Binding
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors targeting Siglec-15 are not explored alongside characterised regulatory mechanisms involving microRNAs in CRC progression. Therefore, a small molecule inhibitor to target Siglec-15 was elucidated in vitro and microRNA mediated inhibitor effects were investigated. Our research findings demonstrated that the SHG-8 molecule exerted significant cytotoxicity on cell viability, migration, and colony formation, with an IC 50 value of approximately 20µM. SHG-8 exposure induced late apoptosis in vitro in SW480 CRC cells. Notably, miR-6715b-3p was the most upregulated miRNA in high-throughput sequencing, which was also validated via RT-qPCR. MiR-6715b-3p may regulate PTTG1IP , a potential oncogene which was validated via RT-qPCR and in silico analysis. Additionally, molecular docking studies revealed SHG-8 interactions with the Siglec-15 binding pocket with the binding affinity of -5.4 kcal/mol, highlighting its role as a small molecule inhibitor. Importantly, Siglec-15 and PD-L1 are expressed on mutually exclusive cancer cell populations, suggesting the potential for combination therapies with PD-L1 antagonists.
45
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Jun Wang, Jingwei Sun, Linda N. Liu et al. · Nature Medicine · 2019 · 697 citations · Full text
Life Sciences, Immunology, Oncology +14
Jiao Hu, Anze Yu, Belaydi Othmane et al. · Theranostics · 2021 · 454 citations · Full text
Medicine, Immunology, Oncology +17